Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07711691 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Empowering Patients' Lung Cancer Screening Uptake (Empower LCS/Call+)

Study acronym: Empower LCS+
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date changed from estimate of Sep 1, 2026 to Sep 16, 2026 · Eligibility criteria expanded, about 10 words · Secondary endpoints: details revised at 7 of 14 entries · 2 more Show 5 more changesShow less
    • Start date changed from estimate of Sep 1, 2026 to Sep 16, 2026
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: details revised at 7 of 14 entries
    • Site details revised at 57 of 57 sites
    • Publications: details revised at 6 of 6 entries
  2. Trial sites expanded: 14 → 57 locationsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Lung cancer screening (LCS) with low-dose computed tomography (LDCT) can reduce the risk of dying from lung cancer, but many people who are eligible for screening do not receive it. The purpose of the Empower LCS/Call+ study is to evaluate new strategies to improve lung cancer screening among adults who are eligible for screening based on current U.S. Preventive Services Task Force (USPSTF) guidelines. This pilot randomized controlled trial will enroll approximately 80 participants from UC Irvine Health and Emory Healthcare. Participants will be randomly assigned to receive either enhanced usual care or the Empower LCS/Call+ intervention. The intervention includes educational materials, reminders for patients and primary care providers, and information about financial and community resources when appropriate. Participants who do not complete lung cancer screening after the initial intervention may receive additional telephone-based navigation through the Call+ program to help identify and address barriers to screening and help with scheduling. Participants will complete a baseline survey and follow-up surveys at 4 and 8 months, and researchers will review electronic health record information to determine whether lung cancer screening was discussed, ordered, and completed. Some participants will also be invited to complete a one-time interview about their experiences with the study. The results of this study will help determine the feasibility, acceptability, and preliminary effectiveness of the Empower LCS/Call+ intervention and will inform future efforts to improve equitable access to lung cancer screening.
Trial Details
NCT Number NCT07711691
Lead Sponsor University of California, Irvine
Conditions Lung Cancer Screening, Lung Neoplasms, Smoking ( Cigarette), Early Detection of Cancer
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov